多囊卵巢综合征患者关键调控分子表达与代谢紊乱的相关性研究

doi:10.3969/j.issn.1006-7795.2026.04.002

首都医科大学学报 ›› 2026, Vol. 47 ›› Issue (4): 643-649.doi: 10.3969/j.issn.1006-7795.2026.04.002

• 更年期妇科内分泌与生育力保护 • 上一篇下一篇

多囊卵巢综合征患者关键调控分子表达与代谢紊乱的相关性研究

赵越¹,阮祥燕^2*,王月姣²,谢丹¹,金婧²,田玄玄²,张煦¹,张娥¹,朱建国¹,张政¹

1.首都医科大学附属北京妇产医院/北京妇幼保健院医务处，北京 100026；2.首都医科大学附属北京妇产医院/北京妇幼保健院内分泌科，北京 100026

收稿日期:2026-03-31 修回日期:2026-04-21 出版日期:2026-08-21 发布日期:2026-07-26
通讯作者: 阮祥燕 E-mail:ruanxiangyan@ccmu.edu.cn
基金资助:
国家自然科学基金项目 (81671411),北京市自然科学基金项目(7162062),首都医科大学附属北京妇产医院“芒种计划”科技创新能力提升专项（FCYYMZB202505）。

Study on the correlation between the expression of key regulatory molecules and metabolic disorders in patients with polycystic ovary syndrome

Zhao Yue¹, Ruan Xiangyan^2*, Wang Yuejiao², Xie Dan¹, Jin Jing², Tian Xuanxuan², Zhang Xu¹, Zhang E¹, Zhu Jianguo¹, Zhang Zheng¹

1.Department of Medical Administration Division, Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care Hospital, Beijing 100026, China；2.Department of Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care Hospital, Beijing 100026, China

Received:2026-03-31 Revised:2026-04-21 Online:2026-08-21 Published:2026-07-26
Supported by:
This study was supported by the National Natural Science Foundation of China (81671411), Beijing Natural Science Foundation (7162062), Mangzhong Technological Innovation Project of Beijing Obstetrics and Gynecology Hospital, Capital Medical University（FCYYMZB202505）.

摘要/Abstract

摘要： 目的探讨孕激素受体膜组分1（progesterone receptor membrane component 1, PGRMC1）在多囊卵巢综合征（polycystic ovary syndrome, PCOS）患者血清中的表达水平及其与高雄激素血症（hyperandrogenemia, HA）、胰岛素抵抗（insulin resistance, IR）和脂代谢紊乱的关联性。方法采用横断面研究设计，纳入首都医科大学附属北京妇产医院就诊的80例PCOS患者和80例同期就诊且年龄、体质量指数（body mass Index, BMI）匹配的健康体检女性。采用酶联免疫吸附剂测定法（enzyme linked immunosorbent assay, ELISA）检测各组血清PGRMC1浓度，液相色谱串联质谱（liquid chromatography-tandem mass spectrometry, LC-MS/MS）测定雄激素指标：总睾酮（total testosterone, TT）、游离睾酮（free testosterone, fT）及生物活性睾酮（bioavailable testosterone, Bio-T），化学发光法检测空腹胰岛素［fasting insulin, FINS(OH)］及血脂谱。多元线性回归及Logistic回归评估PGRMC1与代谢参数的关系。结果 PCOS组血清PGRMC1 水平显著高于对照组［115.23 (67.18,144.36) vs 26.45 (16.94,40.63) ng/L，P<0.001］，且与TT（r=0.693）、fT（r=0.612）、Bio-T（r=0.573）、HOMA-IR（r=0.964）、TG（r=0.401）、低密度脂蛋白胆固醇（r=0.559）呈正相关，与高密度脂蛋白胆固醇（r=－0.228）呈负相关（P均<0.05）。多元线性逐步回归分析显示，HOMA-IR对PGRMC1 有正向影响（B=11.495，P=0.002），该模型拟合度一般（R²=0.114），但模型整体具有统计学意义（F=10.029，P=0.002）。多因素Logistic回归分析证实，PGRMC1（OR=1.039，95% CI：1.025~1.053，P<0.001）和 TG（OR=4.080，95% CI：1.770~9.406，P=0.001）是 PCOS发生的独立危险因素。结论 PGRMC1可能通过调控雄激素合成和胰岛素信号通路参与PCOS代谢紊乱的病理过程，且与TG共同为PCOS的独立危险因素；PGRMC1与IR密切相关，有望成为PCOS诊断及代谢异常评估的分子标志物，为精准诊疗提供新靶点。

关键词: 多囊卵巢综合征, 孕激素受体膜组分1, 高雄激素血症, 胰岛素抵抗, 脂代谢, 三酰甘油

Abstract: Objective To investigate the expression level of progesterone receptor membrane component 1 (PGRMC1) in the serum of patients with polycystic ovary syndrome (PCOS) and its association with hyperandrogenemia (HA), insulin resistance (IR), and dyslipidemia. Methods A cross-sectional study design was adopted, enrolling 80 PCOS patients from Beijing Obstetrics and Gynecology Hospital, Capital Medical University, plus 80 healthy controls with matched age and body mass index (BMI). Serum PGRMC1 concentrations were measured using enzyme-linked immunosorbent assay (ELISA). Androgen indicators—total testosterone (TT), free testosterone (fT), and bioavailable testosterone (Bio-T)—were quantified via liquid chromatography-tandem mass spectrometry (LC-MS/MS). The chemiluminescence was used to test fasting insulin ［FINS(OH)］ and lipid profiles. Multiple linear regression and Logistic regression analyses were utilized to assess the relationship between PGRMC1 and metabolic parameters. Results Serum PGRMC1 concentrations in the PCOS group were significantly higher than that in the control group ［115.23 (67.18, 144.36) vs 26.45 (16.94, 40.63) ng/L, P<0.001］, and is was positively correlated with TT (r=0.693), fT (r=0.612), Bio-T (r=0.573), HOMA-IR (r=0.964), TG (r=0.401), and LDL-C (r=0.559), while showing a negatively association with HDL-C (r=－0.228) (all P<0.05). The results of multiple linear stepwise regression analysis indicated that HOMA-IR had a positive effect on PGRMC1 (B=11.495, P=0.002). The model explained 11.4% of the variance in PGRMC1 (R²=0.114) and was statistically significant overall (F=10.029, P=0.002). Multivariate Logistic regression analysis confirmed that PGRMC1 (OR=1.039, 95% CI: 1.025-1.053, P<0.001) and TG (OR=4.080, 95% CI: 1.770-9.406, P=0.001) were independent risk factors for PCOS. Conclusion PGRMC1 might participate in the pathogenesis of metabolic disorders in PCOS by modulating androgen synthesis and insulin signaling pathways, and together with TG, it serves as an independent risk factor for PCOS. PGRMC1 is closely associated with IR, and is expected to be a molecular marker for PCOS diagnosis and metabolic abnormality assessment, providing a novel target for precision diagnosis and treatment.

Key words: polycystic ovary syndrome, progesterone receptor membrane component 1, hyperandrogenemia, insulin resistance, lipid metabolism, triglyceride

中图分类号:

R711.75

赵越, 阮祥燕, 王月姣, 谢丹, 金婧, 田玄玄, 张煦, 张娥, 朱建国, 张政. 多囊卵巢综合征患者关键调控分子表达与代谢紊乱的相关性研究[J]. 首都医科大学学报, 2026, 47(4): 643-649.

Zhao Yue, Ruan Xiangyan, Wang Yuejiao, Xie Dan, Jin Jing, Tian Xuanxuan, Zhang Xu, Zhang E, Zhu Jianguo, Zhang Zheng. Study on the correlation between the expression of key regulatory molecules and metabolic disorders in patients with polycystic ovary syndrome[J]. Journal of Capital Medical University, 2026, 47(4): 643-649.

参考文献

［1］赵越, 阮祥燕, 崔亚美, 等. 不同亚型的多囊卵巢综合征患者临床及实验室指标特征的研究［J］. 首都医科大学学报, 2015, 36(4): 567-572.
［2］Zhao Y, Ruan X Y, Mueck A O. Clinical and laboratory indicators of polycystic ovary syndrome in Chinese Han nationality with different Rotterdam criteria-based phenotypes［J］. Gynecol Endocrinol, 2016, 32(2): 151-156.
［3］李红丽, 严烩利. 育龄期多囊卵巢综合征患者糖代谢与性激素及子宫内膜容受性的关系［J］. 实用临床医药杂志, 2024, 28 (10): 106-111.
［4］周昕玥, 魏林飞,张学红. PCOS子宫内膜容受性障碍的机制与治疗研究进展［J］. 兰州大学学报(医学版), 2023, 49 (1): 79-86.
［5］Zhang Y Q, Chen Z J, Zhao H. Polycystic ovary syndrome: a metabolic disorder with therapeutic opportunities［J］. Cell Metab, 2025, 37(10): 1932-1949.
［6］Zhao Y, Ruan X, Cheng J, et al. PGRMC1 promotes triple-negative breast cancer cell growth via suppressing ferroptosis［J］. Climacteric, 2023, 26(2): 135-142.
［7］Zhao Y, Ruan X Y. Identifcation of PGRMC1 as a candidate oncogene for head and neck cancers and its involvement in metabolic activities［J］. Front Bioeng Biotechnol, 2020, 7: 438.
［8］Chen H, Cao T, Lin C Q, et al. Akkermansia muciniphila ameliorates olanzapine-induced metabolic dysfunction-associated steatotic liver disease via PGRMC1/SIRT1/FOXO1 signaling pathway［J］. Front Pharmacol, 2025, 16: 1550015.
［9］Peluso J J, Pru C A, Liu X F, et al. Progesterone receptor membrane component 1 and 2 regulate granulosa cell mitosis and survival through a NFΚB-dependent mechanism†［J］. Biol Reprod, 2019, 100(6): 1571-1580.
［10］Furuhata R, Kabe Y, Kanai A, et al. Progesterone receptor membrane associated component 1 enhances obesity progression in mice by facilitating lipid accumulation in adipocytes［J］. Commun Biol, 2020, 3(1): 479.
［11］Zhou J H, Chen Z J, Li J, et al. Expression of PGRMC1 in patients with polycystic ovary syndrome and its molecular mechanism for regulating ovarian granulosa cell apoptosis and glucolipid metabolism［J］. Journal of Central South University (Medical Science), 2023, 48(4): 538-549.
［12］赵越, 阮祥燕, 王月姣, 等. 女性雄性激素质谱多指标检测在多囊卵巢综合征诊断中的应用［J］. 首都医科大学学报, 2024, 45(4): 602-608.
［13］中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵囊综合征中国诊疗指南［J］. 中华妇产科学杂志, 2018, 53(1): 2-6.
［14］翟凤英, 张李伟, 王春荣, 等. 国际生命科学学会中国肥胖问题工作组推荐体重指数分类标准的血脂谱验证［J］. 中华流行病学杂志, 2004, 25(2): 117-119.
［15］Jones D L, Kusinski L C, Gillies C, et al. A critique of measurement of defective insulin secretion and insulin sensitivity as a precision approach to gestational diabetes［J］. Diabetologia, 2025, 68(4): 752-765.
［16］Netaji A, Jain V, Gupta A K, et al. Utility of Mr proton density fat fraction and its correlation with ultrasonography and biochemical markers in nonalcoholic fatty liver disease in overweight adolescents［J］. J Pediatr Endocrinol Metab, 2020, 33(4): 473-479.
［17］中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)［J］. 中国循环杂志, 2023, 38(3): 237-271.
［18］Ahmed I S, Rohe H J, Twist K E, et al. Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule［J］. J Pharmacol Exp Ther, 2010, 333(2): 564-573.
［19］Paulson M, Sahlin L, Hirschberg A L. Progesterone receptors and proliferation of the endometrium in obese women with polycystic ovary syndrome-a lifestyle intervention study［J］. J Clin Endocrinol Metab, 2017, 102(4): 1244-1253.
［20］Schuster J, Karlsson T, Karlström P O, et al. Down-regulation of progesterone receptor membrane component 1 (PGRMC1) in peripheral nucleated blood cells associated with premature ovarian failure (POF) and polycystic ovary syndrome (PCOS)［J］. Reprod Biol Endocrinol, 2010, 8: 58.
［21］Peluso J J. Progesterone signaling and mammalian ovarian follicle growth mediated by progesterone receptor membrane component family members［J］. Cells, 2022, 11(10): 1632.
［22］Thieffry C, Van Wynendaele M, Aynaci A, et al. AG-205 upregulates enzymes involved in cholesterol biosynthesis and steroidogenesis in human endometrial cells independently of PGRMC1 and related MAPR proteins［J］. Biomolecules, 2021, 11(10): 1472.
［23］Zeng C R, Chen H, Cao T, et al. B-GOS alleviates olanzapine-induced lipid disturbances in mice by enriching Akkermansia and upregulation of PGRMC1-Wnt signaling［J］. Food Chem Toxicol, 2024, 185: 114490.
［24］Hampton K K, Anderson K, Frazier H, et al. Insulin receptor plasma membrane levels increased by the progesterone receptor membrane component 1［J］. Mol Pharmacol, 2018, 94(1): 665-673.
［25］Ahmed I S A, Chamberlain C J, Craven R J. S2R(Pgrmc1): the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling［J］. Expert Opin Drug Metab Toxicol, 2012, 8(3): 361-370.
［26］Wu A, Li Y P, Liu R C, et al. Predictive value of insulin resistance as determined by homeostasis model assessment in acute ischemic stroke patients: a systematic review and meta-analysis［J］. Horm Metab Res, 2021, 53(11): 746-751.

[1]	李妍秋, 阮祥燕, 牧青, 蒋玲玲, 张明珍, Alfred O. Mueck. 屈螺酮炔雌醇片和地屈孕酮治疗对超重多囊卵巢综合征患者体成分与脂代谢的影响[J]. 首都医科大学学报, 2026, 47(4): 665-672.
[2]	王麒淇, 郭雨石, 李艳. GDE1参与2型慢性鼻窦炎伴鼻息肉脂代谢通路激活的研究[J]. 首都医科大学学报, 2026, 47(4): 722-729.
[3]	蒋玲玲, 阮祥燕, 李妍秋, 张明珍, 王泽铖, 金婧, 田玄玄, 柳岸鸣. 单用屈螺酮炔雌醇片或联合奥利司他对超重/肥胖多囊卵巢综合征患者排卵恢复率及代谢指标比较[J]. 首都医科大学学报, 2025, 46(4): 607-613.
[4]	田玄玄, 阮祥燕, 赵越, 金婧, 柳顺玉, 蒋玲玲. 个体化生活方式干预对多囊卵巢综合征肥胖患者性功能的影响[J]. 首都医科大学学报, 2025, 46(4): 614-619.
[5]	马郡, 阮祥燕, 许仲婷, 赵越, 王月姣, Alfred O.Mueck. 来曲唑联合资癸女贞胶囊对多囊卵巢综合征子宫内膜薄性不孕患者的疗效观察[J]. 首都医科大学学报, 2025, 46(4): 632-636.
[6]	杨笑, 孟媛媛, 杨靖仪, 王书函, 张立功. 血浆致动脉粥样硬化指数、三酰甘油－葡萄糖指数、脑小血管病影像学标志物对急性缺血性脑卒中患者静脉溶栓早期神经功能恢复的预测价值 [J]. 首都医科大学学报, 2025, 46(1): 48-55.
[7]	赵越, 阮祥燕, 王月姣, 马郡, 金婧. 女性雄性激素质谱多指标检测在多囊卵巢综合征诊断中的应用[J]. 首都医科大学学报, 2024, 45(4): 602-608.
[8]	田玄玄, 阮祥燕, 金婧, 鞠蕊, 杜娟, 程姣姣, 杨瑜. 多囊卵巢综合征患者不同临床表型的性功能分析[J]. 首都医科大学学报, 2024, 45(4): 616-622.
[9]	蒋玲玲, 阮祥燕, 李妍秋, 张明珍, 王泽铖, 杨瑜, 刘莉莉, Alfred O. Mueck. 多囊卵巢综合征患者体成分对肝、肾功能和血脂的影响[J]. 首都医科大学学报, 2024, 45(4): 623-628.
[10]	王泽铖, 阮祥燕, 李婧, 蒋玲玲, Alfred O.Mueck. 医源性早发性卵巢功能不全对脂代谢的影响[J]. 首都医科大学学报, 2023, 44(4): 535-539.
[11]	张明珍, 阮祥燕, 闵敏, Alfred O.Mueck. 奥利司他综合干预对超重或肥胖多囊卵巢综合征患者脂蛋白（a）、糖脂代谢及肝、肾功能的影响[J]. 首都医科大学学报, 2023, 44(4): 544-549.
[12]	田玄玄, 阮祥燕, 金婧, 王娟, 程姣姣. 多囊卵巢综合征患者对生活方式干预获益的认知度调查[J]. 首都医科大学学报, 2023, 44(4): 555-560.
[13]	高霞, 延晋, 姚志, 王广. 三酰甘油葡萄糖指数与新诊断的冠状动脉粥样硬化性心脏病患者冠状动脉病变程度的相关性[J]. 首都医科大学学报, 2023, 44(3): 381-386.
[14]	李晓辉, 尹洁, 刘冰, 于恒池, 祝英娜, 马池发, 袁明霞. 三酰甘油－葡萄糖指数与脂肪组织胰岛素抵抗的关系分析[J]. 首都医科大学学报, 2023, 44(3): 393-399.

多囊卵巢综合征患者关键调控分子表达与代谢紊乱的相关性研究

Study on the correlation between the expression of key regulatory molecules and metabolic disorders in patients with polycystic ovary syndrome

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价